The growing prevalence of chronic diseases is a major factor driving revenue growth in the natural killer (NK) cell ...

Inmagene enrolls first patient in ADAPTIVE phase 2b clinical trial of IMG-007: San Diego Friday, July 4, 2025, 15:00 Hrs [IST] Inmagene Biopharmaceuticals (Inmagene), a clinical-s ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

AbbVie has announced a definitive agreement to acquire Capstan Therapeutics, a clinical-stage biotechnology company, for up ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the ...

AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today ...

During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

Furthermore, Gal-9 was cytotoxic for chemoresistant Sc-1 cells (Sc-1-RES), which were even more sensitive toward Gal-9 treatment than the parental cells (Sc-1-PAR). Thus, Gal-9 potently induced cell ...

The interplay between viruses and tumor progression represents a critical area of study, as certain oncogenic viruses, such as HPV, EBV, and HBV, are known ...

Recent advancements in dermatology have highlighted the crucial role of dermal T cell immunity in regulating hair follicle regeneration and ...

Recent advancements in dermatology have highlighted the crucial role of dermal T cell immunity in regulating hair follicle regeneration and addressing ...

Antiretroviral therapy (ART) initiated in the acute phase of HIV infection (AHI) results in a smaller viral reservoir. However, the impact of early HIV-specific T-cell responses on long-term reservoir ...